SCD ‐ related SAEs ‐ ACS · prevention of SCI in people with SCD and normal TCD velocities
Long‐term RBC transfusion may leads to lower SCD ‐ related SAEs ‐ ACS compared with standard care (low certainty).
1 finding from 1 review
SCD‐related SAEs ‐ pain crisis · prevention of SCI in people with SCD and normal TCD velocities
Long‐term RBC transfusion may leads to lower SCD‐related SAEs ‐ pain crisis compared with standard care (low certainty).
1 finding from 1 review
Stroke · prevention of SCI in people with SCD and normal TCD velocities
Long‐term RBC transfusion showed no clear difference in clinical stroke compared with standard care (low certainty).
1 finding from 1 review
Cognitive function · prevention of SCI in people with SCD and normal TCD velocities
1 finding from 1 review
Quality of life · prevention of SCI in people with SCD and normal TCD velocities
1 finding from 1 review
Proportion of participants developing new or progressive SCI lesions · prevention of SCI in people with SCD and abnormal TCD velocities
Long‐term RBC transfusion may leads to lower proportion of participants developing new or progressive SCI lesions compared with standard care (low certainty).
1 finding from 1 review
All‐cause mortality · prevention of SCI in people with SCD and abnormal TCD velocities
1 finding from 1 review
CBA: Average duration of sickness absence periods in days · workers
2 findings from 1 review
CBA: Number of sickness absence periods per worker · workers
2 findings from 1 review
CBA: Average lost work time per 100 person‐years · workers
2 findings from 1 review
RCT: Costs of sickness absence and physician certification · workers
1 finding from 1 review
Adherence · participants with recurrent herpes labialis
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
2 findings from 1 review
Duration of attack of herpes labialis during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with oral omega‐6 PUFAs (moderate certainty).
1 finding from 1 review
Ocular surface staining · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in ocular surface staining at 1‐month compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs may leads to higher adverse event: gastrointestinal disorders at 1‐month (with actual compared with oral omega‐6 PUFAs (low certainty).
1 finding from 1 review